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Abstract
Background: Anaesthesia is commonly employed prior to surgical investigations and to permit
icv injections in rodents. Indeed it is standard practise in many studies examining the subsequent
actions of hormones and growth factors on the brain. Recent evidence that the basal activity of
specific intracellular signalling proteins can be affected by anaesthesia prompted us to examine the
effect of anaesthesia not only on the basal activity but also the insulin sensitivity of the major insulin
signalling pathways.
Results: We find that urethane- and ketamine-induced anaesthesia results in rapid activation of the
phosphatidylinositol (PI) 3-kinase-protein kinase B (PKB) signalling pathway in the brain, increases
tau phosphorylation while at the same time reducing basal activity of the Ras-ERK pathway.
Subsequent injection of insulin does not alter the activity of either the PI 3-kinase or ERK signalling
pathways, indicating a degree of neuronal molecular insulin resistance. However, if body
temperature is maintained during anaesthesia then there is no alteration in the basal activity of
these signalling molecules. Subsequent response of both pathways to insulin injection is restored.
Conclusion: The data is consistent with a hypothermia related alteration in neuronal signalling
following anaesthesia, and emphasises the importance of maintaining the body temperature of
rodents when monitoring insulin (or growth factor/neurotrophic agent) action in the brain of
anesthetised rodents.
Background
Insulin is produced by pancreatic β-cells, in response to
rising plasma glucose levels, and initiates multiple meta-
bolic changes to restore glucose homeostasis. A specific
membrane glycoprotein acts as a high affinity sensor for
insulin (insulin receptor (IR)) in many tissues (primarily
liver, fat, muscle). The IR is expressed in many regions of
the brain, including the hypothalamus, cortex, and hip-
pocampus. Neuron specific deletion of the IR makes the
animal more sensitive to diet induced obesity [1], impli-
cating neuronal IR in the satiety response. Consistent with
this, administration of insulin to the arcuate nucleus in
the hypothalamus has significant effects on feeding and
body weight [2-4].
Epidemiological evidence suggests that whole body insu-
lin resistance, related to obesity, increases the risk of
Alzheimer's disease, as well as vascular dementia [5-7]. In
Published: 9 October 2008
BMC Neuroscience 2008, 9:100 doi:10.1186/1471-2202-9-100
Received: 16 May 2008
Accepted: 9 October 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/100
© 2008 Holscher et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:100 http://www.biomedcentral.com/1471-2202/9/100
Page 2 of 7
(page number not for citation purposes)
addition, there are molecular links between the develop-
ment of Type 2 diabetes (an insulin resistant state) and
Alzheimers's disease [8]. For example, GSK3β activity is
increased in the muscle of Type 2 diabetics [9] and the
brain of Alzheimer's patients [10]. This enzyme is inhib-
ited by insulin treatment of cells [11], and is known to be
a major tau kinase, phosphorylating residues that become
hyperphosphorylated in Alzheimer's disease [12]. There-
fore, insulin resistance in the brain may contribute to a
major component of Alzheimer's disease pathology.
Binding of insulin to the IR activates the intrinsic tyrosine
kinase domain of the IR [13,14]. Insulin receptor sub-
strate (IRS) proteins are recruited to the activated IR,
become phosphorylated on tyrosine residues [13],
thereby recruiting PI 3-kinase, which converts phosphoi-
nositol 4,5 bisphosphate (PIP2) to phosphoinositol 3,4,5
trisphosphate (PIP3) [15]. This second messenger then
brings pleckstrin homology (PH) domain containing pro-
teins to the membrane, activating protein kinase cascades.
The best characterised of these is the phosphoinositide
dependent protein kinase (PDK1) pathway. PDK1 regu-
lates many protein kinases, including protein kinase B
(PKB, also known as Akt), PKC, p90 RSK, p70S6K and
SGK [16]. These protein kinases phosphorylate and regu-
late a wide variety of proteins involved in growth and
metabolism. For example, PKB phosphorylates and inac-
tivates GSK3 [11], and FOXO transcription factors [17].
These pathways are important for the proper regulation of
hepatic gene transcription by insulin [18,19].
The second major pathway downstream of IRSs is the Ras-
ERK pathway. Grb2/mSOS is a protein complex that inter-
acts with phosphorylated IRSs (at distinct residues to
those that recruit PI 3-kinase). Once bound, mSOS
exchanges GDP for GTP on the small G-protein Ras,
thereby activating Ras [20]. This promotes activation of c-
Raf, which phosphorylates and activates MAP/ERK kinase
(MEK), which in turn phosphorylates and activates ERK1/
2 [20-22]. ERK1/2 has multiple substrates, most of which
are related to cell growth, hence this pathway is generally
considered to be important in insulin regulation of
growth.
Most studies examining insulin action in the brain utilise
primary neurons, slice culture or transgenic animals.
However, direct application of insulin to the brain, by
intracerebroventricular (icv) injection, can be used to
study acute and chronic effects of insulin in vivo. Recent
evidence suggests that some of the signalling molecules
described above are affected by anaesthesia [23,24],
which is commonly used prior to icv injection. In this
report we examined the two major insulin signalling path-
ways in the brain of anaesthetised rodents, and find that
anaesthesia induced hypothermia generates insulin resist-
ance in the brain.
Methods
Anaesthesia and ICV injections
Male C57/Bl6 mice 3 months of age were obtained from
Harlan, UK. All studies were performed under the regula-
tions permitted by UK home office licence no. PPL2603b.
Animals were fasted overnight and anesthetised by ip
injection of either urethane (750 mg/kg dose in 0.2 ml) or
ketamine/Xylazine (80–100 mg/kg + 10 mg/kg).
For some studies (as indicated in figure legends) anesthe-
tised animals were kept at 37°C by use of a temperature
controlled heating pad (Harvard apparatus, rectal probe).
For icv injection of insulin (3 mU in 2 μl), animals were
injected with ketamine/Xylazine, put into a stereotaxic
frame (TSE systems, Germany), the scalp was removed,
and a 0.7 mm hole was drilled to permit injection into the
lateral ventricle using a 5 μl Hamilton syringe (coordi-
nates from bregma: AP = 0.2, ML = 1.2, D = 2.5). Animals
were injected immediately with sterile saline solution
(control) or insulin. The injection was given slowly over 2
minutes. Body temperature was approximately 34°C by
the time of the icv injection.
After 30 min, animals were decapitated, the brains
removed and dissected into different brain sections. Brain
sections were then snap frozen in dry ice and stored at -40
until analysis. Non-anesthetised controls were injected ip
with saline and were decapitated after 30 min without any
surgery, and the brains removed and snap frozen.
Antibodies
Antibodies to phospho-PKB (Thr308), phospho-PKB
(Ser473), phospho-ERK (Thr202/Tyr204), were from Cell
Signaling Technology (Beverly, MA, U.S.A.), antibodies to
total PKB, ERK1/2 and GSK3α/β were from Upstate Bio-
technologies (Lake Placid, NY, U.S.A.). Anti-β-Actin was
purchased from Sigma-Aldrich, Inc. (St Louis, MO,
U.S.A.). The phospho-tau (AT8) and tau-5 (total tau) anti-
bodies were purchased from Innogenetics (Gent, Bel-
gium) and Chemicon, respectively.
Tissue Homogenisation and Immunoblot
Frozen tissues were homogenised using a 1 ml glass
Dounce homogenizer in lysis buffer containing 1% (v/v)
Triton X-100, 50 mM Tris-HCl, pH 7.5, 0.27 M sucrose, 1
mM sodium orthovanadate, 0.1% (v/v) β-mercaptoetha-
nol and Complete protease inhibitor tablets (Roche,
Lewes, UK) (4°C). Following centrifugation, supernatants
were collected and protein concentrations determined
[25]. Lysates (typically 2.5–30 μg) were subjected to SDS-
PAGE on 4–12% NuPAGE polyacrylamide gels, then
transferred to nitrocellulose membrane. Membranes wereBMC Neuroscience 2008, 9:100 http://www.biomedcentral.com/1471-2202/9/100
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incubated with primary antibodies (diluted 1/1000 in 1%
(w/v) skimmed milk or 5% (w/v) BSA in TTBS overnight
at 4°C), appropriate HRP-linked secondary antibodies,
then visualised using the ECL reagent (GE Healthcare)
and exposed to autorad film (GE Healthcare).
Analysis of data
Densitometry was performed using Aida computer soft-
ware (Raytest, Straubenhardt, Germany). Phosphoryla-
tion of ERK, Akt and tau were calculated as the ratio of the
phosphospecific versus total protein antibody signal,
while phosphorylation of GSK3 was a ratio of the P-GSK3
to β-actin (loading control). Mean values were calculated
for each sample and the control value was set at 1. Data is
presented as mean ± standard deviation, and statistical
significance (p-value) between two conditions was
obtained using an unpaired students t-test.
Results and discussion
Anaesthesia induces changes in the major insulin regulated 
protein kinase cascades resulting in loss of subsequent 
response to insulin
Eight mice were anesthetised with Ketamine/Xylazine,
and four were sacrificed without anaesthesia (Fig. 1). Half
Anaesthesia induces neuronal insulin resistance Figure 1
Anaesthesia induces neuronal insulin resistance. Mice were injected i.p. with either urethane or ketamine/Xylazine (K/
X). Half of the K/X group were given insulin by icv injection, the other half received saline, 30 mins prior to sacrifice and rapid 
removal and dissection of the brain. Control animals were sacrificed without anaesthesia or icv injection. Equal amounts of cor-
tical protein were subjected to western blot using the specific antibodies shown (A-representative blots), and results from 4 
animals in each treatment group were quantified by densitometry (B). The mean ± SD, relative to the control animals, is 
shown. Significant differences between control and each treatment group are given, *p < 0.05, **p < 0.005, ns, not significant. 
Body temperature of all animals during anaesthesia was monitored and is presented as mean ± SD (C).BMC Neuroscience 2008, 9:100 http://www.biomedcentral.com/1471-2202/9/100
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of the Ketamine/Xylazine group were injected icv with 3
mU of insulin and the rest with an equivalent volume of
saline. The phosphorylation of protein kinase B (PKB) at
both Ser-308 and Thr-473 is used as a surrogate for activa-
tion [26]. Meanwhile the phosphorylation of the PKB tar-
get, GSK3β (at Ser-9), is a measure of intracellular PKB
activation [11]. ERK1/2 phosphorylation at Thr-202/Tyr-
204 provides a measure of the activity state of this key
enzyme [21]. Surprisingly, we found no significant effect
of insulin on these pathways in the cortex (Fig. 1) or hip-
pocampus (data not shown). However, the level of phos-
phorylation of PKB and GSK3 was significantly higher in
the anesthetised animals, compared to animals that had
been sacrificed without anaesthesia (Fig. 1). The same
abnormally high signalling was observed with either ket-
amine or urethane administration (Fig. 1). This suggests
increased basal PKB activity in the anaesthetised animals.
In contrast, the phosphorylation of ERK1/2 decreased fol-
lowing anaesthesia (Fig. 1), but as with the PKB pathway,
there was no subsequent regulation of ERK by insulin.
This suggested that the anaesthesia itself was altering the
signalling pathways in a manner that prevented regula-
tion by insulin. Reduced ERK and increased GSK3 phos-
phorylation have been reported previously in rodents
exposed to various anaesthetics [23,24]. However, this is
the first demonstration of abnormal phosphorylation of
PKB and importantly, of subsequent loss of response of all
of these pathways to insulin. The molecular mecha-
nism(s) leading from anaesthesia to induction of PKB
activity and repression of ERK activity is not entirely clear.
Reduced activity of the protein phosphatase, PP2A, has
been found in rodents anesthetised by pentobarbital, and
this could be prevented by maintaining body temperature
[24]. The increased PKB and GSK3 phosphorylation may
be explained by reduced PP2A activity but it is more diffi-
cult to understand the lower ERK phosphorylation. Most
growth factors (and insulin) will induce both of these
pathways, however, dysregulation of the Ras-ERK path-
way has been observed in polycystic ovarian syndrome
(PCOS) ([27] and CS unpublished data), which is charac-
terised by hyperandrogenism and insulin resistance. The
molecular pathology of the defective ERK signalling in
PCOS remains to be determined, and indeed it is still
unclear whether the insulin resistance precedes or is sub-
sequent to the abnormal regulation of ERK in PCOS.
The previous reports of abnormal signalling processes in
anaesthesia had indicated that the induction of hypother-
mia contributed to the defective signalling. Indeed, sim-
ply lowering body temperature could alter ERK and GSK3
signalling [24]. The body temperature of the animals
injected with either agent was substantially and reproduc-
ibly lowered within the timeframe of the experiment (Fig.
1C). Although it is quite likely that many other physiolog-
ical processes (including hypoxia) will be induced by
anaesthesia, we investigated whether maintenance of
body temperature of the anesthetised animals prevented
the defective response of PKB, GSK3 or ERK1/2 phospho-
rylation to insulin.
Maintenance of body temperature during anaesthesia is 
required to permit intracellular responses to insulin in the 
brain
There was a significant insulin induction of both of the
PKB-GSK3 and Ras-ERK pathways in the cortex and hip-
pocampus of the anesthetised animals when body tem-
perature was maintained at 37°C (Fig. 2). Significant
increases in phosphorylation of Thr308 and Ser473 of
PKB, Ser21/9 of GSK3 and Thr202/Tyr204 of ERK were
detected following insulin administration (Fig. 2B), while
the changes in basal phosphorylation of ERK and PKB
were not observed in anaesthetised animals when body
temperature was maintained (Fig. 2C). Therefore, the
maintenance of body temperature during anaesthesia is
absolutely required for insulin activation of these signal-
ling pathways.
This is of particular importance since prolonged insulin
resistance in the brain is likely to underlie the increased
risk of dementia in people with Type 2 diabetes (for
review see [8]). The insulin resistance generated by anaes-
thesia-associated hypothermia may provide a model sys-
tem to study the neurodegenerative effects of insulin
resistance and/or the neuroprotective effects of insulin, in
vivo. Post-operative cognitive defects have been widely
reported, particularly in the elderly, and these may be
related to general anaesthesia [28,29]. Meanwhile, obesity
induced insulin resistance leads to cognitive impairment
in rodents [30,31]. Therefore insulin resistance in the
brain during anaesthesia may play an important role in
postoperative cognitive decline, although it is unlikely
that body temperature falls below 30°C in clinical prac-
tice, therefore further study is required to establish the
exact point where hypothermia is problematic.
The data presented shows the importance of maintaining
body temperature in rodents undergoing anaesthesia
prior to studies investigating hormonal or growth factor
regulation of cognition. The signalling molecules affected
by hypothermia are not only key to the action of insulin
in the brain, but also the action of neurotrophic agents
and other circulating hormones (e.g. Leptin) [4].
The phosphorylation of tau at Ser202/Thr205 is induced by 
anaesthesia but remains sensitive to insulin
Hyperphosphorylation of tau, on numerous residues,
associates with the development of Alzheimer's disease
and other forms of dementia (tauopathies). Previous
work demonstrated that tau phosphorylation increases
during anaesthesia [24]. We found that tau phosphoryla-BMC Neuroscience 2008, 9:100 http://www.biomedcentral.com/1471-2202/9/100
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tion (at Ser202/Thr205) was increased by urethane or ket-
amine (Fig. 3). However, in contrast to the complete loss
of insulin activation of the PKB and ERK pathways, there
was an additive induction of tau phosphorylation follow-
ing insulin in the anaesthetised animals (Fig. 3). This sug-
gests that these residues do not become completely
phosphorylated during anaesthesia, and that insulin regu-
lation of this site is not going through the ERK or PKB
pathways. The extent of tau phosphorylation in response
to insulin was greater when body temperature was main-
tained, presumably due to the lower basal phosphoryla-
tion (Fig. 3B). Insulin resistance has been implicated as an
'accelerator' of Alzheimer's pathology. The anaesthetised
animal may provide a model to establish which phospho-
rylation events on tau are regulated by the ERK and PKB
pathways in response to insulin, and whether anaesthesia
worsens the pathology in models of Alzheimer's disease.
Conclusion
Anaesthesia induces abnormal signalling in the brain, but
this can be prevented by maintaining body temperature.
The abnormal signalling produces a form of molecular
insulin resistance, although this is not equally severe in all
insulin signalling pathways. Anaesthesia/hypothermia
Insulin sensitivity is maintained during anaesthesia if hypothermia is prevented Figure 2
Insulin sensitivity is maintained during anaesthesia if hypothermia is prevented. Mice were injected i.p. with keta-
mine/Xylazine (K/X), and body temperature maintained at 37°C. Half of the group (n = 4) were given insulin by icv injection, 
the other half (n = 4) received saline 30 mins prior to sacrifice and rapid removal and dissection of the brain. Equal amounts of 
cortical protein were subjected to western blot using the antibodies shown (A), and results from each treatment group quan-
tified by densitometry (B). The mean ± SD, relative to the control animals, is shown. Significant differences between control 
and each treatment group are given, *p < 0.05, **p < 0.005. Phosphorylation of ERK and PKB was also compared between ani-
mals sacrificed without anaesthesia and those with anaesthesia but whose body temperature was maintained at 37°C (C).BMC Neuroscience 2008, 9:100 http://www.biomedcentral.com/1471-2202/9/100
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Tau phosphorylation is increased by anaesthesia but remains partially sensitive to insulin even during hypothermia Figure 3
Tau phosphorylation is increased by anaesthesia but remains partially sensitive to insulin even during hypo-
thermia. Samples described in Fig. 2 and Fig. 3 were analysed for phosphorylation of tau (A-representative blots) at Ser202 
and Thr205 (AT8 antibody), and for total tau (tau-5 antibody). The results from each treatment group were quantified by den-
sitometry (B). The mean ± SD, relative to the control animals, is shown. Significant differences between control and each treat-
ment group are given, *p < 0.05, **p < 0.005.BMC Neuroscience 2008, 9:100 http://www.biomedcentral.com/1471-2202/9/100
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has potential as an in vivo model for the study of the effect
of insulin resistance in the brain. Meanwhile great care
must be taken to maintain body temperature when using
anesthetised rodents to study neuronal signalling.
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